SimBioSysは、NVIDIAの技術を活用したFDAクリアランス取得済みの乳がん再発リスク推定ツールTumorSight Riskを提供している。既存の乳房MRIを病理および臨床情報と組み合わせ、5年および10年後のがん再発リスクを推定する。HR陽性かつHER2陰性の早期乳がん患者は、手術前にこの分析結果を得て、治療選択肢を検討する際に医師と情報を共有できる。
After a breast cancer diagnosis, one of the hardest questions is whether it will come back.
@SimBioSys is helping doctors and patients better understand that risk. Powered by NVIDIA technology, its FDA-cleared TumorSight Risk analyzes an existing breast MRI alongside pathology and clinical information to estimate the risk of cancer returning at five and ten years.
For women with HR-positive, HER2-negative early-stage breast cancer, those insights can be available before surgery, giving them and their doctors more information as they talk through treatment options.
AI can help give patients and their doctors more information when the decisions ahead feel most difficult.
出典: NVIDIA · x.com